Ingevity (NGVT) Given a $110.00 Price Target at Oppenheimer

Ingevity (NYSE:NGVT) has been assigned a $110.00 target price by investment analysts at Oppenheimer in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 13.40% from the stock’s current price.

Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Ingevity from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a report on Thursday, November 22nd. Jefferies Financial Group set a $68.00 price objective on shares of Ingevity and gave the stock a “buy” rating in a report on Thursday, December 20th. Loop Capital set a $95.00 price objective on shares of Ingevity and gave the stock a “hold” rating in a report on Thursday, December 13th. Finally, Stifel Nicolaus began coverage on shares of Ingevity in a report on Monday, December 10th. They set a “hold” rating and a $84.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $95.33.

NYSE NGVT opened at $97.00 on Thursday. The company has a market cap of $3.87 billion, a PE ratio of 37.60, a PEG ratio of 1.64 and a beta of 1.55. The company has a debt-to-equity ratio of 2.31, a current ratio of 2.34 and a quick ratio of 1.26. Ingevity has a 1-year low of $70.71 and a 1-year high of $106.59.

Institutional investors have recently modified their holdings of the stock. Fruth Investment Management increased its holdings in shares of Ingevity by 5.1% in the fourth quarter. Fruth Investment Management now owns 8,679 shares of the company’s stock valued at $726,000 after purchasing an additional 419 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Ingevity by 39.6% in the third quarter. Glenmede Trust Co. NA now owns 4,442 shares of the company’s stock valued at $452,000 after purchasing an additional 1,260 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of Ingevity in the third quarter valued at approximately $3,577,000. Royce & Associates LP increased its holdings in shares of Ingevity by 110.2% in the third quarter. Royce & Associates LP now owns 104,157 shares of the company’s stock valued at $10,612,000 after purchasing an additional 54,600 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Ingevity in the third quarter valued at approximately $786,000. 95.64% of the stock is owned by institutional investors and hedge funds.

Ingevity Company Profile

Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells wood-based chemically activated carbon products primarily for gasoline vapor emission control systems.

Featured Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Ingevity (NYSE:NGVT)

Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply